spot_img
Monday, May 23, 2022
More
    HomeHealthPatent thickets thwart U.S. availability of lower-cost biosimilars

    Patent thickets thwart U.S. availability of lower-cost biosimilars

    -

    [ad_1]

    Amid debate over competitors within the pharmaceutical trade, a brand new evaluation discovered simply 6% of patents lined key components — or modern new molecules — in expensive biologic medicines, underscoring issues that drug makers abuse the patent system after they go to courtroom to thwart rivals.

    The researchers examined 21 patent infringement lawsuits filed by pharmaceutical corporations in opposition to different drug makers and recognized 179 patents that have been allegedly infringed. However most have been for so-called secondary makes use of, or much less essential than makes use of listed in major patents. As an illustration, 42% lined manufacturing processes, 35% lined different methods to make use of a medication, and 34% lined formulations.

    Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!

    GET STARTED



    [ad_2]

    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,324FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts